FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 18, 2026
Moleculin Biotech, Inc. (MBRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $33.6 million. Free cash flow was -$22.7 million. As of Jun 30, 2026 it held $7.3 million in cash and investments and $292,000 in total debt.
Revenue (TTM)
$0
Net income (TTM)
$-30.33M
+18.7% vs year-ago TTM
Operating cash flow (TTM)
$-25.36M
-18.8% vs year-ago TTM
Free cash flow
$-22.73M
+4.8% vs prior year
EPS
—
Dividend per share
None
Shares outstanding
5.34M
-61.9% vs prior year
Net cash
$6.97M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MBRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1659617
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$25.1M | -$26.6M | -$29.6M | -$30.6M | -$23.0M |
| Net income | -$33.6M | -$26.0M | -$29.8M | -$29.0M | -$15.9M |
| Operating cash flow | -$22.7M | -$23.9M | -$23.6M | -$27.6M | -$19.0M |
| Free cash flow | -$22.7M | -$23.9M | -$23.7M | -$27.7M | -$19.0M |
| Total assets | $22.1M | $16.9M | $38.2M | $57.4M | $84.1M |
| Total liabilities | $7.1M | $5.7M | $12.1M | $5.2M | $5.1M |
| Stockholders' equity | $15.0M | $11.2M | $30.9M | $52.2M | $79.0M |
| Cash and investments | $8.9M | $4.3M | $23.6M | $43.1M | $70.9M |
| Total debt | $359,000 | $478,000 | $574,000 | $451,000 | $159,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 30, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Oct 20, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 16, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 5, 2026 | Oct 5, 2026 |
All 838 Moleculin Biotech, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.